Showing 2685 results
-
Key Release /Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is…
-
Press Release /First of multiple agreements being explored by Novartis to leverage manufacturing capacity and capabilities to address pandemic, supporting global supply of COVID-19 vaccine Initial agreement signed…
-
Press Release /Designation in patients with chronic myeloid leukemia (CML) resistant or intolerant to prior treatments based on positive data from pivotal Phase III ASCEMBL trial evaluating asciminib, an…
-
Press Release /Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Press Release /Sandoz to acquire three established brands sold in more than 100 marketsAcquisition, including leading global brand Zinnat®, confirms Sandoz commitment to antibiotics, following plans to expand its…
-
Press Release /Project brings together Novartis drug discovery and gene therapy expertise and funding support from the Gates Foundation Agreement aims to address disparity in access to treatments and to…
-
Key Release /Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction (…
-
Press Release /Adds tislelizumab, a uniquely designed anti-PD-1 monoclonal antibody for monotherapy and proprietary combination cancer therapies with Novartis portfolio and pipeline therapies Novartis will co-…
-
Press Release /Cosentyx® (secukinumab) is the first biologic with proven efficacy in all 6 key manifestations of psoriatic arthritis (PsA), and the only biologic with fast and lasting relief of axial manifestations…
-
Press Release /Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien…